Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Applications of human endometrium stem cells in preparation of drugs for premature ovarian failure treatment

A technology for premature ovarian failure and stem cells, which can be used in drug combinations, pharmaceutical formulations, medical preparations containing active ingredients, etc., and can solve the problems of limited proliferation ability, limited cell sources, and traumatic access methods.

Inactive Publication Date: 2015-11-18
THE INT PEACE MATERNITY & CHILD HEALTH HOSPITAL OF CHINA WELFARE INST +1
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, the clinical use of bone marrow stem cells has certain limitations, such as limited source of cells, limited proliferation ability, traumatic acquisition methods, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of human endometrium stem cells in preparation of drugs for premature ovarian failure treatment
  • Applications of human endometrium stem cells in preparation of drugs for premature ovarian failure treatment
  • Applications of human endometrium stem cells in preparation of drugs for premature ovarian failure treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] Example 1, identification of human endometrial stem cells

[0073] Cell Source and Culture

[0074] The human endometrial stem cell line MP135 is derived from the menstrual blood of a 40-year-old Chinese woman. The third-generation cells of MP135 were provided by Professor Xiang Chunsheng of Zhejiang University. The use of human cells was approved by the Ethics Committee of the International Peace Maternal and Child Health Hospital Affiliated to Shanghai Jiaotong University.

[0075] MP135 cells were grown in stem cell medium containing endometrium / menstruation [13], placed in 5% CO 2 37°C incubator. The cells were digested with trypsin, subcultured, and when the cell fusion rate reached 80-90%, subsequent experiments were performed.

[0076] Flow Cytometry Analysis

[0077] The specific markers CD29, CD90, CD34, CD45, CD117, HLA-DR and OCT4 on the surface of MP135 cells were analyzed by flow cytometry. details as follows:

[0078] Resuspend MP135 cells (make the c...

Embodiment 2

[0084] Example 2, human endometrial stem cell transplantation can promote the recovery of mouse body weight and estrous cycle

[0085] Animal experiment

[0086] 1. Select 6-week-old C57BL / 6 wild-type female mice (60), and establish an animal model of premature ovarian failure by intraperitoneally injecting busulfan (30 mg / kg) and cyclophosphamide (120 mg / kg);

[0087] 2. Also select age-matched female mice for intraperitoneal injection of DMSO as the experimental control group (10);

[0088] 3. One week after chemotherapeutic drug injection, the animals were anesthetized by intraperitoneal injection of sodium pentobarbital (45mg / kg);

[0089] 4. Put (2×10 6 cells) Human endometrial stem cells were injected into mice through tail vein;

[0090] 5. The control group was given the same dose of cell culture fluid in the same way;

[0091] 6. One week after transplantation of human endometrial stem cells, the changes of estrous cycle and body weight of mice were observed by va...

Embodiment 3

[0112] Example 3. Transplantation of human endometrial stem cells can restore the fertility of mice

[0113] In order to study the effect of human endometrial stem cell transplantation on the fertility of mice, female mice in different groups were paired with normal male mice for a 3-month mating experiment starting from the 8th week after cell transplantation. The number of pregnancies and litter sizes of mice in different groups were statistically analyzed. The results showed that the use of chemotherapeutic drugs significantly reduced the fertility of mice (including the number of pregnancies and average litter size). The mice in the cell transplantation group and the normal control group had three successful pregnancies, but the animals in the chemotherapy group had only two pregnancies, including stillbirth ( Figure 4 A). Although the average litter size per female mouse in the cell transplantation group was significantly higher than that in the chemotherapy drug contr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a new method for premature ovarian failure treatment, wherein human endometrium stem cells can promote ovarian function recovery. Particularly the present invention discloses applications of human endometrium stem cells in preparation of drugs for premature ovarian failure treatment, specifically in preparation of cell drugs for premature ovarian failure treatment, and / or medical technologies.

Description

technical field [0001] The invention relates to a new method for treating premature ovarian failure: human endometrium stem cells help to promote the recovery of ovarian function. Background technique [0002] Premature Ovarian Failure (POF) refers to the termination of menstrual periods in women before the age of 40 due to depletion of ovarian follicles or iatrogenic damage; it is a common gynecological disease mainly manifested as estrogen deficiency and elevated follicle-stimulating hormone ; Is the main cause of female infertility [1]. Studies have shown that the probability of premature ovarian failure in women aged 30 to 40 is about 1-2%, that of women under 30 is 0.1%, and that of women under 20 is 0.01%. It is characterized by younger age and high incidence [2,3]. Early failure of ovarian function causes patients to lose their fertility prematurely, and the decline in estrogen levels leads to an increase in the risk of osteoporosis and cardiovascular diseases, seri...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/48A61P15/08
Inventor 赖东梅项春生舒敏张秋婉牟晓洲
Owner THE INT PEACE MATERNITY & CHILD HEALTH HOSPITAL OF CHINA WELFARE INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com